^
BIOMARKER:
KRAS G12V
i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
›
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
panitumumab Sensitive: B - Late Trials
|
panitumumab Sensitive: B - Late Trials
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
cetuximab Resistant: B - Late Trials
|
cetuximab Resistant: B - Late Trials
|
KRAS G12V
|
Ovarian Serous Adenocarcinoma
|
KRAS G12V
|
Ovarian Serous Adenocarcinoma
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
KRAS G12V
|
Ovarian Cancer
|
KRAS G12V
|
Ovarian Cancer
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
KRAS G12V
|
Spindle Cell Sarcoma
|
KRAS G12V
|
Spindle Cell Sarcoma
|
BAL3833 Sensitive: C3 – Early Trials
|
BAL3833 Sensitive: C3 – Early Trials
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
KRAS G12V
|
HCC
|
KRAS G12V
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
VS-6766 Sensitive: C3 – Early Trials
|
VS-6766 Sensitive: C3 – Early Trials
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
RGX-202 Sensitive: C3 – Early Trials
|
RGX-202 Sensitive: C3 – Early Trials
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
bevacizumab + PCM-075 Sensitive: C3 – Early Trials
|
bevacizumab + PCM-075 Sensitive: C3 – Early Trials
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
FOLFOX Resistant: C3 – Early Trials
|
FOLFOX Resistant: C3 – Early Trials
|
KRAS G12V
|
Lung Non-Squamous Non-Small Cell Cancer
|
KRAS G12V
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
KRAS G12V
|
LUAD
|
KRAS G12V
|
LUAD
|
osimertinib Resistant: C4 – Case Studies
|
osimertinib Resistant: C4 – Case Studies
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
AZ 628 Resistant: D – Preclinical
|
AZ 628 Resistant: D – Preclinical
|
KRAS G12V
|
Colon Cancer
|
KRAS G12V
|
Colon Cancer
|
CDK9 inhibitor Sensitive: D – Preclinical
|
CDK9 inhibitor Sensitive: D – Preclinical
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
selumetinib + AZ 628 Sensitive: D – Preclinical
|
selumetinib + AZ 628 Sensitive: D – Preclinical
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
selumetinib Resistant: D – Preclinical
|
selumetinib Resistant: D – Preclinical
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
sunitinib Resistant: D – Preclinical
|
sunitinib Resistant: D – Preclinical
|
KRAS G12V
|
Ovarian Cancer
|
KRAS G12V
|
Ovarian Cancer
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
KRAS G12V
|
CRC
|
KRAS G12V
|
CRC
|
P1446A-05 Sensitive: D – Preclinical
|
P1446A-05 Sensitive: D – Preclinical
|
KRAS G12V
|
NSCLC
|
KRAS G12V
|
NSCLC
|
pembrolizumab Sensitive: D – Preclinical
|
pembrolizumab Sensitive: D – Preclinical
|
KRAS G12V
|
Pancreatic Cancer
|
KRAS G12V
|
Pancreatic Cancer
|
BMF-219 Sensitive: D – Preclinical
|
BMF-219 Sensitive: D – Preclinical
|
